Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029386022> ?p ?o ?g. }
- W2029386022 endingPage "903" @default.
- W2029386022 startingPage "895" @default.
- W2029386022 abstract "Background We have shown that the endogenous stimulation of cannabinoid type-1 (CB1) receptors is a prerequisite for voluntary running in mice, but the precise mechanisms through which the endocannabinoid system exerts a tonic control on running performance remain unknown. Methods We analyzed the respective impacts of constitutive/conditional CB1 receptor mutations and of CB1 receptor blockade on wheel-running performance. We then assessed the consequences of ventral tegmental area (VTA) CB1 receptor blockade on the wheel-running performances of wildtype (gamma-aminobutyric acid [GABA]-CB1+/+) and mutant (GABA-CB1–/–) mice for CB1 receptors in brain GABA neurons. Using in vivo electrophysiology, the consequences of wheel running on VTA dopamine (DA) neuronal activity were examined in GABA-CB1+/+ and GABA-CB1–/– mice. Results Conditional deletion of CB1 receptors from brain GABA neurons, but not from several other neuronal populations or from astrocytes, decreased wheel-running performance in mice. The inhibitory consequences of either the systemic or the intra-VTA administration of CB1 receptor antagonists on running behavior were abolished in GABA-CB1–/– mice. The absence of CB1 receptors from GABAergic neurons led to a depression of VTA DA neuronal activity after acute/repeated wheel running. Conclusions This study provides evidence that CB1 receptors on VTA GABAergic terminals exert a permissive control on rodent voluntary running performance. Furthermore, it is shown that CB1 receptors located on GABAergic neurons impede negative consequences of voluntary exercise on VTA DA neuronal activity. These results position the endocannabinoid control of inhibitory transmission as a prerequisite for wheel-running performance in mice. We have shown that the endogenous stimulation of cannabinoid type-1 (CB1) receptors is a prerequisite for voluntary running in mice, but the precise mechanisms through which the endocannabinoid system exerts a tonic control on running performance remain unknown. We analyzed the respective impacts of constitutive/conditional CB1 receptor mutations and of CB1 receptor blockade on wheel-running performance. We then assessed the consequences of ventral tegmental area (VTA) CB1 receptor blockade on the wheel-running performances of wildtype (gamma-aminobutyric acid [GABA]-CB1+/+) and mutant (GABA-CB1–/–) mice for CB1 receptors in brain GABA neurons. Using in vivo electrophysiology, the consequences of wheel running on VTA dopamine (DA) neuronal activity were examined in GABA-CB1+/+ and GABA-CB1–/– mice. Conditional deletion of CB1 receptors from brain GABA neurons, but not from several other neuronal populations or from astrocytes, decreased wheel-running performance in mice. The inhibitory consequences of either the systemic or the intra-VTA administration of CB1 receptor antagonists on running behavior were abolished in GABA-CB1–/– mice. The absence of CB1 receptors from GABAergic neurons led to a depression of VTA DA neuronal activity after acute/repeated wheel running. This study provides evidence that CB1 receptors on VTA GABAergic terminals exert a permissive control on rodent voluntary running performance. Furthermore, it is shown that CB1 receptors located on GABAergic neurons impede negative consequences of voluntary exercise on VTA DA neuronal activity. These results position the endocannabinoid control of inhibitory transmission as a prerequisite for wheel-running performance in mice." @default.
- W2029386022 created "2016-06-24" @default.
- W2029386022 creator A5000286738 @default.
- W2029386022 creator A5004656976 @default.
- W2029386022 creator A5014737965 @default.
- W2029386022 creator A5023021929 @default.
- W2029386022 creator A5034935327 @default.
- W2029386022 creator A5035014109 @default.
- W2029386022 creator A5036547376 @default.
- W2029386022 creator A5040998161 @default.
- W2029386022 creator A5045500471 @default.
- W2029386022 creator A5053388087 @default.
- W2029386022 creator A5055367429 @default.
- W2029386022 creator A5073028848 @default.
- W2029386022 creator A5076502894 @default.
- W2029386022 creator A5091732504 @default.
- W2029386022 date "2013-05-01" @default.
- W2029386022 modified "2023-10-17" @default.
- W2029386022 title "Ventral Tegmental Area Cannabinoid Type-1 Receptors Control Voluntary Exercise Performance" @default.
- W2029386022 cites W1597278618 @default.
- W2029386022 cites W1966476393 @default.
- W2029386022 cites W1969415886 @default.
- W2029386022 cites W1970162156 @default.
- W2029386022 cites W1975748753 @default.
- W2029386022 cites W1978830550 @default.
- W2029386022 cites W1979174743 @default.
- W2029386022 cites W1980153635 @default.
- W2029386022 cites W1982186440 @default.
- W2029386022 cites W1982506365 @default.
- W2029386022 cites W1983272530 @default.
- W2029386022 cites W1988182239 @default.
- W2029386022 cites W1989330097 @default.
- W2029386022 cites W1989353122 @default.
- W2029386022 cites W1992557727 @default.
- W2029386022 cites W1995338592 @default.
- W2029386022 cites W1996940119 @default.
- W2029386022 cites W1997128521 @default.
- W2029386022 cites W2007977381 @default.
- W2029386022 cites W2017543199 @default.
- W2029386022 cites W2018305067 @default.
- W2029386022 cites W2018991110 @default.
- W2029386022 cites W2020808135 @default.
- W2029386022 cites W2020847861 @default.
- W2029386022 cites W2027150013 @default.
- W2029386022 cites W2036768211 @default.
- W2029386022 cites W2037457092 @default.
- W2029386022 cites W2044711161 @default.
- W2029386022 cites W2048546110 @default.
- W2029386022 cites W2055638785 @default.
- W2029386022 cites W2059079970 @default.
- W2029386022 cites W2067312146 @default.
- W2029386022 cites W2073982465 @default.
- W2029386022 cites W2080649553 @default.
- W2029386022 cites W2083721478 @default.
- W2029386022 cites W2086635661 @default.
- W2029386022 cites W2093130323 @default.
- W2029386022 cites W2094843557 @default.
- W2029386022 cites W2095758186 @default.
- W2029386022 cites W2099878623 @default.
- W2029386022 cites W2104436602 @default.
- W2029386022 cites W2112755850 @default.
- W2029386022 cites W2116268998 @default.
- W2029386022 cites W2119826244 @default.
- W2029386022 cites W2122487138 @default.
- W2029386022 cites W2124178069 @default.
- W2029386022 cites W2124580147 @default.
- W2029386022 cites W2125842400 @default.
- W2029386022 cites W2133702956 @default.
- W2029386022 cites W2137881661 @default.
- W2029386022 cites W2150821313 @default.
- W2029386022 cites W2155801131 @default.
- W2029386022 cites W2162661460 @default.
- W2029386022 cites W2163421692 @default.
- W2029386022 cites W2164142910 @default.
- W2029386022 cites W2166092191 @default.
- W2029386022 cites W2169340948 @default.
- W2029386022 cites W4321429251 @default.
- W2029386022 doi "https://doi.org/10.1016/j.biopsych.2012.10.025" @default.
- W2029386022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23237313" @default.
- W2029386022 hasPublicationYear "2013" @default.
- W2029386022 type Work @default.
- W2029386022 sameAs 2029386022 @default.
- W2029386022 citedByCount "80" @default.
- W2029386022 countsByYear W20293860222013 @default.
- W2029386022 countsByYear W20293860222014 @default.
- W2029386022 countsByYear W20293860222015 @default.
- W2029386022 countsByYear W20293860222016 @default.
- W2029386022 countsByYear W20293860222017 @default.
- W2029386022 countsByYear W20293860222018 @default.
- W2029386022 countsByYear W20293860222019 @default.
- W2029386022 countsByYear W20293860222020 @default.
- W2029386022 countsByYear W20293860222021 @default.
- W2029386022 countsByYear W20293860222022 @default.
- W2029386022 countsByYear W20293860222023 @default.
- W2029386022 crossrefType "journal-article" @default.
- W2029386022 hasAuthorship W2029386022A5000286738 @default.
- W2029386022 hasAuthorship W2029386022A5004656976 @default.
- W2029386022 hasAuthorship W2029386022A5014737965 @default.